https://www.selleckchem.com/products/ipi-549.html
The lenvatinib (LEN) plus everolimus (EVE) combination demonstrated improved progression-free survival over everolimus alone in a phase 2 trial (Study-205). To compare quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) between LEN + EVE and EVE alone among patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy. This was a post hoc analysis of Study-205. Survival time was partitioned into three mutually exclusive health states time with grade 3/4 toxicity (TOX); time
Like
Comment
Share
